## Diane Damotte

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/10578151/diane-damotte-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103<br/>papers7,218<br/>citations40<br/>h-index84<br/>g-index113<br/>ext. papers9,164<br/>ext. citations6.2<br/>avg, IF5.32<br/>L-index

#	Paper	IF	Citations
103	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101777	2.2	1
102	Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients <i>Lung Cancer</i> , <b>2022</b> , 166, 221-227	5.9	1
101	CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFN and ICAM-1. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 1425-1438	12.5	3
100	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.	8.8	1
99	EBioMedicine, 2021, 73, 103630 CXCR6 deficiency impairs cancer vaccine efficacy and CD8 resident memory T-cell recruitment in head and neck and lung tumors 2021, 9,		7
98	Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 626776	8.4	9
97	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 891-908	12.5	7
96	Size and Predictive Factors of Microscopic Tumor Extension in Locally Advanced Non-Small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , <b>2021</b> , 11, 491-501	2.8	1
95	Metabolic features of cancer cells impact immunosurveillance <b>2021</b> , 9,		2
94	Mutational landscape of gray zone lymphoma. <i>Blood</i> , <b>2021</b> , 137, 1765-1776	2.2	15
93	ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, e686-e690	4.9	O
92	Gene expression profiling of gray zone lymphoma. <i>Blood Advances</i> , <b>2020</b> , 4, 2523-2535	7.8	10
91	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1037-1053	8.9	27
90	PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920937972	5.4	9
89	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	34
88	Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage. <i>Cancers</i> , <b>2020</b> , 12,	6.6	18
87	Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study). <i>OncoTargets and Therapy</i> , <b>2020</b> , 13, 13299-1.	3 <del>3</del> : <del>0</del> 5	Ο

## (2019-2020)

86	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions <b>2020</b> , 8,		24	
85	Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6	
84	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 16641	4.9	5	
83	Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes. <i>Cancer Genomics and Proteomics</i> , <b>2020</b> , 17, 587-595	3.3	3	
82	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 497-505	3.5	3	
81	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , <b>2020</b> , 39, 1893-1899	5.9	7	
80	: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. <i>Oncology Letters</i> , <b>2019</b> , 18, 3471-3480	2.6	6	
79	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy <b>2019</b> , 7, 121		46	
78	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. <i>OncoImmunology</i> , <b>2019</b> , 8, e1581556	7.2	40	
77	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 844-856	8.9	27	
76	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, S89-S101	2.6	43	
75	Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. <i>Cancer Letters</i> , <b>2019</b> , 464, 5-14	9.9	62	
74	Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 405-411	4.9	7	
73	Unexpected pulmonary tumour in a young woman. <i>Journal of Clinical Pathology</i> , <b>2019</b> , 72, 783	3.9	O	
72	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 357	8.5	32	
71	Mutational Landscape of Grey Zone Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 21-21	2.2	1	
70	Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). <i>Blood</i> , <b>2019</b> , 134, 2832-2832	2.2	3	
69	Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management. <i>Annals of Thoracic Surgery</i> , <b>2019</b> , 107, 1053-1059	2.7	16	

68	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 341-351	6.7	37
67	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. <i>EBioMedicine</i> , <b>2019</b> , 48, 191-202	8.8	31
66	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
65	Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. <i>OncoImmunology</i> , <b>2019</b> , 8, e1505174	7.2	20
64	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 928-940	10.2	38
63	Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E4041-E4050	11.5	323
62	Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. <i>OncoImmunology</i> , <b>2018</b> , 7, e1423184	7.2	26
61	Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. <i>Oncotarget</i> , <b>2018</b> , 9, 9088-9099	3.3	18
60	, and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5710-5723	12.9	150
59	Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. <i>Haematologica</i> , <b>2017</b> , 102, 150-159	6.6	44
58	Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	23
57	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , <b>2017</b> , 12, 301-308	5	47
56	Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. <i>Lung Cancer</i> , <b>2017</b> , 113, 93-101	5.9	21
55	Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought. <i>Lung</i> , <b>2017</b> , 195, 789-798	2.9	22
54	Thoracic Endometriosis Syndrome Other Than Pneumothorax: Clinical and Pathological Findings. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 1865-1871	2.7	19
53	Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. <i>Investigational New Drugs</i> , <b>2017</b> , 35, 842-847	4.3	12
52	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. <i>Oncotarget</i> , <b>2017</b> , 8, 44960-44975	3.3	57
51	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2008-2017	2.2	98

50	Correlation between radiological and pathological features of operated ground glass nodules. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2017</b> , 51, 248-254	3	1
49	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. <i>Oncolmmunology</i> , <b>2017</b> , 6, e135	8 <del>3</del> 30	12
48	Body Mass Index and Total Psoas Area Affect Outcomes in Patients Undergoing Pneumonectomy for Cancer. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 103, 287-295	2.7	45
47	Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy. <i>Journal of Visualized Experiments</i> , <b>2017</b> ,	1.6	8
46	Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget, <b>2017</b> , 8, 23831-23840	3.3	42
45	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. <i>Science Immunology</i> , <b>2016</b> , 1, aaf6925	28	93
44	Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. American Journal of Respiratory and Critical Care Medicine, <b>2016</b> , 194, 1403-1412	10.2	34
43	Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , <b>2016</b> , 76, 1746-56	10.1	122
42	Estrogen Therapy Delays Autoimmune Diabetes and Promotes the Protective Efficiency of Natural Killer T-Cell Activation in Female Nonobese Diabetic Mice. <i>Endocrinology</i> , <b>2016</b> , 157, 258-67	4.8	15
41	mRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4523-4523	2.2	
40	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 923-30	7.1	61
39	Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. <i>OncoImmunology</i> , <b>2016</b> , 5, e1255394	7.2	34
38	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3031-40	12.9	249
37	A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4 T cell receptor repertoire clonality. <i>Oncolmmunology</i> , <b>2015</b> , 4, e1051922	7.2	55
36	The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 191, 377-90	10.2	140
35	Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience. <i>Lung</i> , <b>2015</b> , 193, 965-73	2.9	13
34	Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 500	8.4	70
33	Epidemiology of spontaneous pneumothorax: gender-related differences. <i>Thorax</i> , <b>2015</b> , 70, 653-8	7.3	91

32	The immune contexture of primary and metastatic human tumours. <i>Current Opinion in Immunology</i> , <b>2014</b> , 27, 8-15	7.8	85
31	TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 5008-18	10.1	64
30	Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 832-44	10.2	340
29	Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 131	8.5	20
28	Pneumothorax in women of child-bearing age: an update classification based on clinical and pathologic findings. <i>Chest</i> , <b>2014</b> , 145, 354-360	5.3	42
27	The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. <i>Chest</i> , <b>2014</b> , 146, 633-643	5.3	70
26	Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. <i>Cancer Research</i> , <b>2014</b> , 74, 705-15	10.1	306
25	Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e106914	3.7	101
24	Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. <i>Oncotarget</i> , <b>2014</b> , 5, 8252-69	3.3	40
23	The immune microenvironment of human tumors: general significance and clinical impact. <i>Cancer Microenvironment</i> , <b>2013</b> , 6, 117-22	6.1	93
22	Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2013</b> , 145, 1305-11	1.5	18
21	Prognostic significance of vascular and lymphatic emboli in resected pulmonary adenocarcinoma. <i>Annals of Thoracic Surgery</i> , <b>2013</b> , 95, 1204-10	2.7	17
20	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , <b>2013</b> , 12, 543-4	4.7	1
19	Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4079-91	12.9	213
18	Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 899-910	15.9	486
17	Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. <i>PLoS ONE</i> , <b>2011</b> , 6, e17621	3.7	71
16	Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2011</b> , 142, 1161-7	1.5	50
15	Pneumothorax recurrence after surgery in women: clinicopathologic characteristics and management. <i>Annals of Thoracic Surgery</i> , <b>2011</b> , 92, 322-6	2.7	32

## LIST OF PUBLICATIONS

14	Tumor microenvironment is multifaceted. Cancer and Metastasis Reviews, 2011, 30, 13-25	9.6	86
13	Immune infiltration in human cancer: prognostic significance and disease control. <i>Current Topics in Microbiology and Immunology</i> , <b>2011</b> , 344, 1-24	3.3	126
12	Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 6391-9	10.1	196
11	Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. <i>Cancer Research</i> , <b>2011</b> , 71, 5412-22	10.1	302
10	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 1285-97	15.9	153
9	CD4+CD25+ T cells play a complex role in the pediatric combined liver-intestinal graft acceptance. <i>Transplantation</i> , <b>2010</b> , 90, 95-7	1.8	2
8	Study of the impact of liver transplantation on the outcome of intestinal grafts in children. <i>Transplantation</i> , <b>2006</b> , 81, 992-7	1.8	25
7	Effector memory T cells, early metastasis, and survival in colorectal cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2654-66	59.2	1560
7		59.2 6.1	1560
	Medicine, 2005, 353, 2654-66  IL-10 is necessary for FasL-induced protection from experimental autoimmune thyroiditis but not		
6	Medicine, 2005, 353, 2654-66  IL-10 is necessary for FasL-induced protection from experimental autoimmune thyroiditis but not for FasL-induced immune deviation. European Journal of Immunology, 2002, 32, 1292-9  An interval tightly linked to but distinct from the H2 complex controls both overt diabetes (Idd16) and chronic experimental autoimmune thyroiditis (Ceat1) in nonobese diabetic mice. Diabetes,	6.1	10
6 5	Medicine, 2005, 353, 2654-66  IL-10 is necessary for FasL-induced protection from experimental autoimmune thyroiditis but not for FasL-induced immune deviation. European Journal of Immunology, 2002, 32, 1292-9  An interval tightly linked to but distinct from the H2 complex controls both overt diabetes (Idd16) and chronic experimental autoimmune thyroiditis (Ceat1) in nonobese diabetic mice. Diabetes, 2002, 51, 2141-7  Up-to-date evolution of small bowel transplantation in children with intestinal failure. Journal of	6.1	10
6 5	IL-10 is necessary for FasL-induced protection from experimental autoimmune thyroiditis but not for FasL-induced immune deviation. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 1292-9  An interval tightly linked to but distinct from the H2 complex controls both overt diabetes (Idd16) and chronic experimental autoimmune thyroiditis (Ceat1) in nonobese diabetic mice. <i>Diabetes</i> , <b>2002</b> , 51, 2141-7  Up-to-date evolution of small bowel transplantation in children with intestinal failure. <i>Journal of Pediatric Surgery</i> , <b>1999</b> , 34, 841-3; discussion 843-4	6.1 0.9 2.6	10